Treating the Motor Symptoms of Parkinson Disease

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Purpose of Review: After a patient is diagnosed with Parkinson disease (PD), there are many therapeutic options available. This article provides examples of prototypical patients encountered in clinical practice and illustrates the various pharmacologic and nonpharmacologic treatment options for the motor symptoms of PD. Recent Findings: Levodopa became available in the late 1960s and remains the gold standard for the treatment of PD even today. Since that time, amantadine, monoamine oxidase type B inhibitors, dopamine agonists, and catechol-O-methyltransferase inhibitors have emerged as monotherapy, add-on therapies, or both, in the armamentarium against PD. The most appropriate time to start such drugs remains a clinical decision according to patient symptoms. However, earlier use of levodopa is the more common practice due to its superior benefit and the side effects of dopamine agonists. Deep brain stimulation continues to be the most effective treatment for motor symptoms in appropriate patients, and advances in technology may improve efficacy. New ways to deliver levodopa have emerged (effective extended-release oral preparations and levodopa/carbidopa intestinal gel), and these medications provide additional options for certain patients. Exercise and neurorehabilitation are increasingly recognized as important tools to combat the motor symptoms of PD. Nondopaminergic drugs may help non-levodopa-responsive motor symptoms. Summary: Treatment of PD is multifaceted and requires a tailored pharmacotherapeutic and nonpharmacologic approach for a given patient. Patients should be at the center of care, and clinicians should try to provide optimum benefit through the many treatment options available.

Original languageEnglish (US)
Pages (from-to)1064-1085
Number of pages22
JournalCONTINUUM Lifelong Learning in Neurology
Volume22
Issue number4,MovementDisorders
DOIs
StatePublished - Aug 1 2016

Fingerprint

Parkinson Disease
Levodopa
Dopamine Agonists
Therapeutics
Amantadine
Deep Brain Stimulation
Monoamine Oxidase Inhibitors
Pharmaceutical Preparations
Gels
Exercise
Technology

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Treating the Motor Symptoms of Parkinson Disease. / Morgan, John Christopher; Fox, Susan H.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 22, No. 4,MovementDisorders, 01.08.2016, p. 1064-1085.

Research output: Contribution to journalReview article

Morgan, John Christopher ; Fox, Susan H. / Treating the Motor Symptoms of Parkinson Disease. In: CONTINUUM Lifelong Learning in Neurology. 2016 ; Vol. 22, No. 4,MovementDisorders. pp. 1064-1085.
@article{319b2299fd484dcbba96f5e6b86edfc9,
title = "Treating the Motor Symptoms of Parkinson Disease",
abstract = "Purpose of Review: After a patient is diagnosed with Parkinson disease (PD), there are many therapeutic options available. This article provides examples of prototypical patients encountered in clinical practice and illustrates the various pharmacologic and nonpharmacologic treatment options for the motor symptoms of PD. Recent Findings: Levodopa became available in the late 1960s and remains the gold standard for the treatment of PD even today. Since that time, amantadine, monoamine oxidase type B inhibitors, dopamine agonists, and catechol-O-methyltransferase inhibitors have emerged as monotherapy, add-on therapies, or both, in the armamentarium against PD. The most appropriate time to start such drugs remains a clinical decision according to patient symptoms. However, earlier use of levodopa is the more common practice due to its superior benefit and the side effects of dopamine agonists. Deep brain stimulation continues to be the most effective treatment for motor symptoms in appropriate patients, and advances in technology may improve efficacy. New ways to deliver levodopa have emerged (effective extended-release oral preparations and levodopa/carbidopa intestinal gel), and these medications provide additional options for certain patients. Exercise and neurorehabilitation are increasingly recognized as important tools to combat the motor symptoms of PD. Nondopaminergic drugs may help non-levodopa-responsive motor symptoms. Summary: Treatment of PD is multifaceted and requires a tailored pharmacotherapeutic and nonpharmacologic approach for a given patient. Patients should be at the center of care, and clinicians should try to provide optimum benefit through the many treatment options available.",
author = "Morgan, {John Christopher} and Fox, {Susan H.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1212/CON.0000000000000355",
language = "English (US)",
volume = "22",
pages = "1064--1085",
journal = "CONTINUUM Lifelong Learning in Neurology",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "4,MovementDisorders",

}

TY - JOUR

T1 - Treating the Motor Symptoms of Parkinson Disease

AU - Morgan, John Christopher

AU - Fox, Susan H.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose of Review: After a patient is diagnosed with Parkinson disease (PD), there are many therapeutic options available. This article provides examples of prototypical patients encountered in clinical practice and illustrates the various pharmacologic and nonpharmacologic treatment options for the motor symptoms of PD. Recent Findings: Levodopa became available in the late 1960s and remains the gold standard for the treatment of PD even today. Since that time, amantadine, monoamine oxidase type B inhibitors, dopamine agonists, and catechol-O-methyltransferase inhibitors have emerged as monotherapy, add-on therapies, or both, in the armamentarium against PD. The most appropriate time to start such drugs remains a clinical decision according to patient symptoms. However, earlier use of levodopa is the more common practice due to its superior benefit and the side effects of dopamine agonists. Deep brain stimulation continues to be the most effective treatment for motor symptoms in appropriate patients, and advances in technology may improve efficacy. New ways to deliver levodopa have emerged (effective extended-release oral preparations and levodopa/carbidopa intestinal gel), and these medications provide additional options for certain patients. Exercise and neurorehabilitation are increasingly recognized as important tools to combat the motor symptoms of PD. Nondopaminergic drugs may help non-levodopa-responsive motor symptoms. Summary: Treatment of PD is multifaceted and requires a tailored pharmacotherapeutic and nonpharmacologic approach for a given patient. Patients should be at the center of care, and clinicians should try to provide optimum benefit through the many treatment options available.

AB - Purpose of Review: After a patient is diagnosed with Parkinson disease (PD), there are many therapeutic options available. This article provides examples of prototypical patients encountered in clinical practice and illustrates the various pharmacologic and nonpharmacologic treatment options for the motor symptoms of PD. Recent Findings: Levodopa became available in the late 1960s and remains the gold standard for the treatment of PD even today. Since that time, amantadine, monoamine oxidase type B inhibitors, dopamine agonists, and catechol-O-methyltransferase inhibitors have emerged as monotherapy, add-on therapies, or both, in the armamentarium against PD. The most appropriate time to start such drugs remains a clinical decision according to patient symptoms. However, earlier use of levodopa is the more common practice due to its superior benefit and the side effects of dopamine agonists. Deep brain stimulation continues to be the most effective treatment for motor symptoms in appropriate patients, and advances in technology may improve efficacy. New ways to deliver levodopa have emerged (effective extended-release oral preparations and levodopa/carbidopa intestinal gel), and these medications provide additional options for certain patients. Exercise and neurorehabilitation are increasingly recognized as important tools to combat the motor symptoms of PD. Nondopaminergic drugs may help non-levodopa-responsive motor symptoms. Summary: Treatment of PD is multifaceted and requires a tailored pharmacotherapeutic and nonpharmacologic approach for a given patient. Patients should be at the center of care, and clinicians should try to provide optimum benefit through the many treatment options available.

UR - http://www.scopus.com/inward/record.url?scp=84982878880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982878880&partnerID=8YFLogxK

U2 - 10.1212/CON.0000000000000355

DO - 10.1212/CON.0000000000000355

M3 - Review article

C2 - 27495198

AN - SCOPUS:84982878880

VL - 22

SP - 1064

EP - 1085

JO - CONTINUUM Lifelong Learning in Neurology

JF - CONTINUUM Lifelong Learning in Neurology

SN - 1080-2371

IS - 4,MovementDisorders

ER -